Cassava Sciences Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SPUS | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $59.51 |
52-Week Low | $0.87 | $46.28 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
SPUS trades at $59.16, up 0.82% today, with a bullish technical signal from moving averages but bearish oscillators. Recent dividends of $0.03 per share were declared for mid-2026. The stock shows strong institutional interest and competitive dividend strategies amid market concentration in tech stocks.
Outlook remains positive due to dividend stability and technical support, but overbought RSI signals caution. Risks include market volatility and reliance on dividend performance. Analysts monitor earnings growth as a key catalyst for sustained upside.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →